India takes a stand against a popular painkiller, nimesulide, with a ban on high doses, citing severe health risks. But is this move enough to protect public health?
The Story Unfolds:
The Indian government has taken a significant step in safeguarding public health by banning high doses of nimesulide, a painkiller and anti-fever medication widely used across the country. The decision, effective December 31, 2025, restricts the drug's use to doses below 100 mg, addressing concerns over its potential to cause liver damage, which can be fatal in some cases.
This isn't the first time nimesulide has been under scrutiny. In January 2025, India banned all veterinary formulations of the drug due to its impact on vulture populations, a move prompted by a CDSCO panel's advice. The drug's toxicity to vultures, as revealed by a joint study by the Bombay Natural History Society and the Indian Council of Agricultural Research, was alarming, with vultures dying within 24 hours of administration.
A Troubled History:
Nimesulide, sold under various brand names, has a controversial past. Introduced in Italy in 1985 as an NSAID (non-steroidal anti-inflammatory drug), it was never approved in several major countries, including the US, UK, Canada, and Japan, due to safety concerns. Side effects like stomach pain, nausea, and skin rashes were noted, and prolonged use could lead to severe liver and kidney damage.
Global Concerns:
The International Society of Drug Bulletins, a WHO-supported network, called for a global ban in 2008, emphasizing the drug's lack of therapeutic advantage over other NSAIDs and its higher risk of liver disorders. This led to its withdrawal in several countries, yet India continued its use, albeit with restrictions for children under 12 since 2011.
Recent Developments:
In March 2023, the Indian Pharmacopoeia Commission raised alarms about fixed drug eruptions, a type of recurrent skin rash, associated with nimesulide. This prompted a call for closer monitoring of the drug's safety.
The Big Question:
While the recent ban addresses high doses, should India consider a complete ban on nimesulide, given its controversial history and the availability of alternative painkillers? The debate continues, leaving room for discussion on the balance between drug accessibility and public health safety.
Stay tuned for more health-related updates and feel free to share your thoughts on this critical issue.
